J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wells, T
Right arrow Articles by Shahinfar, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wells, T
Right arrow Articles by Shahinfar, S
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension

T Wells, V Frame, B Soffer, W Shaw, Z Zhang, P Herrera, and S Shahinfar

Despite widespread use to treat childhood hypertension, enalapril has never been studied systematically to determine effectiveness, dose response, and safety in a pediatric population. This study was conducted prospectively in 110 hypertensive children ages 6 to 16 years in two sequential phases. The primary outcome variable for both phases of the study was trough (24-h postdose) sitting diastolic blood pressure. The primary objective of the first phase of the study was to determine whether enalapril lowered blood pressure in children in a dose-dependent manner. During a 2-week, double-blind, randomized, dose-response period, patients were stratified by weight (< 50 kg or > or = 50 kg), then assigned to one of three dosing groups: low(0.625 or 1.25 mg), middle (2.5 or 5 mg), or high dose (20 or 40 mg). Reduction in blood pressure was examined as a function of dose ratio (1:4:32) and on a weight-adjusted basis. On completion of the dose-response phase of the study, patients entered a 2-week, double-blind, randomized withdrawal to either enalapril or placebo. Antihypertensive effectiveness, defined as the difference in sitting diastolic blood pressure between the placebo and enalapril groups, was determined. Adverse events were carefully recorded throughout the study. The dose-response relationship for enalapril had a negative slope and was linear over the chosen dosing range, suggesting that larger doses of enalapril were associated with a greater reduction in blood pressure. Randomized withdrawal to active drug orplacebo confirmed the antihypertensive effectiveness of enalapril in the middle- and high-dose groups. The antihypertensive effect of enalapril was maintained across age, gender, race, and Tanner stage. Enalapril appears to be an effective and generally well-tolerated antihypertensive agent in children ages 6 to 16 years. An initial dose of 2.5 mg in children weighing < 50 kg and 5 mg in children weighing > 50 kg (mean = 0.08 mg/kg) administered once daily effectively lowered blood pressure within 2 weeks in most patients. Blood pressure was reduced in a dose-dependent fashion, with larger doses resulting in a greater reduction.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 HypertensionHome page
S.-H. Wan, M. Hart, and I. Hajjar
A Novel Measurement Index for Antihypertensive Medication Burden and Its Use
Hypertension, November 1, 2009; 54(5): e135 - e136.
[Full Text] [PDF]

Home page
 J Clin PharmacolHome page
J. Blumer, D. L. Batisky, T. Wells, V. Shi, S. Solar-Yohay, and G. Sunkara
Pharmacokinetics of Valsartan in Pediatric and Adolescent Subjects With Hypertension
J. Clin. Pharmacol., February 1, 2009; 49(2): 235 - 241.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
J. T. Flynn, K. E.C. Meyers, J. P. Neto, R. de Paula Meneses, A. Zurowska, A. Bagga, L. Mattheyse, V. Shi, J. Gupte, S. Solar-Yohay, et al.
Efficacy and Safety of the Angiotensin Receptor Blocker Valsartan in Children With Hypertension Aged 1 to 5 Years
Hypertension, August 1, 2008; 52(2): 222 - 228.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
D. K. Benjamin Jr, P. B. Smith, P. Jadhav, J. V. Gobburu, M. D. Murphy, V. Hasselblad, C. Baker-Smith, R. M. Califf, and J. S. Li
Pediatric Antihypertensive Trial Failures: Analysis of End Points and Dose Range
Hypertension, April 1, 2008; 51(4): 834 - 840.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
J. S. Li, K. Berezny, R. Kilaru, L. Hazan, R. Portman, R. Hogg, R. D. Jenkins, P. Kanani, C. M. Cottrill, T. K. Mattoo, et al.
Is the Extrapolated Adult Dose of Fosinopril Safe and Effective in Treating Hypertensive Children?
Hypertension, September 1, 2004; 44(3): 289 - 293.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
National High Blood Pressure Education Program Wor
The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents
Pediatrics, August 1, 2004; 114(2/S2): 555 - 576.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American College of Clinical Pharmacology